TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
This agreement is in addition to the $92 million filling line expansion announced in November 2021
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Includes thermostabilized Ebola vaccines
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Subscribe To Our Newsletter & Stay Updated
